Literature DB >> 8567821

Insulin resistant and non-resistant polycystic ovary syndrome represent two clinical and endocrinological subgroups.

D Meirow1, O Yossepowitch, A Rösler, A Brzezinski, J G Schenker, N Laufer, I Raz.   

Abstract

We studied the clinical and endocrine features of 35 patients with polycystic ovary syndrome (PCOS) who are either insulin resistant or non-insulin resistant. The occurrence of insulin resistance was determined by measuring insulin and glucose concentrations following a standard 75 g oral glucose load. All patients were evaluated by anthropometric measurements: body mass index (BMI), percentage of body fat (BCF) and waist-to-hip ratio (W/H), degree of hirsutism (Ferriman-Gallwey method) and endocrine profile. Fourteen patients had insulin resistance of unknown origin whereas four were due to a type A insulin receptor mutation, and 17 were non-insulin resistant. The insulin resistant patients were significantly more obese (higher BMI P < 0.0001, BCF P < 0.002 and W/H ratio P < 0.005) and were more hirsute (P < 0.002) than the non-insulin resistant patients. Testosterone concentrations were significantly higher in the insulin resistant group than in the non-insulin resistant group (2.65 versus 1.37 nmol/l; P < 0.027), whereas sex hormone-binding globulin was lower in insulin resistant patients (30.61 versus 19.48 nmol/l; P < 0.02). Non-insulin resistant patients showed a high luteinizing hormone to follicle stimulating hormone ratio, while a normal ratio was found in the insulin resistant subpopulation (2.94 versus 1.34; P < 0.0001). We concluded that PCOS comprises two subpopulations, one with insulin resistance of different aetiologies and the other which has no insulin resistance. These two groups differ in their anthropometric and endocrine features. The diagnosis of insulin resistance in PCOS can be easily determined by the insulin response to an oral glucose tolerance test.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8567821     DOI: 10.1093/oxfordjournals.humrep.a136215

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  7 in total

1.  The presence of antibodies to oxidative modified proteins in serum from polycystic ovary syndrome patients.

Authors:  J R Palacio; A Iborra; Z Ulcova-Gallova; R Badia; P Martínez
Journal:  Clin Exp Immunol       Date:  2006-05       Impact factor: 4.330

2.  Effect of rosiglitazone on endocrine, metabolism and ovulatory performance in patients with polycystic ovary syndrome and insulin resistance.

Authors:  Liqun Lv; Yi Liu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2004

3.  Effects of hyperandrogenemia and increased adiposity on reproductive and metabolic parameters in young adult female monkeys.

Authors:  W K McGee; C V Bishop; C R Pohl; R J Chang; J C Marshall; F K Pau; R L Stouffer; J L Cameron
Journal:  Am J Physiol Endocrinol Metab       Date:  2014-04-15       Impact factor: 4.310

4.  Pharmacological treatment of obesity in patients with polycystic ovary syndrome.

Authors:  Hassan Kahal; Stephen L Atkin; Thozhukat Sathyapalan
Journal:  J Obes       Date:  2010-12-15

Review 5.  Resistance to the Insulin and Elevated Level of Androgen: A Major Cause of Polycystic Ovary Syndrome.

Authors:  Haigang Ding; Juan Zhang; Feng Zhang; Songou Zhang; Xiaozhen Chen; Wenqing Liang; Qiong Xie
Journal:  Front Endocrinol (Lausanne)       Date:  2021-10-20       Impact factor: 5.555

6.  Current trends in the treatment of polycystic ovary syndrome with desire for children.

Authors:  Margalida E Sastre; Maria O Prat; Miguel Angel Checa; Ramon C Carreras
Journal:  Ther Clin Risk Manag       Date:  2009-05-20       Impact factor: 2.423

7.  Transport of deoxy-D-glucose into lymphocytes of patients with polycystic ovary syndrome.

Authors:  Bożenna Oleszczak; Leszek Szablewski; Monika Pliszka; Olgierd Głuszak; Urszula Stopińska-Głuszak
Journal:  Endocrine       Date:  2014-02-11       Impact factor: 3.633

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.